Lin Shan-Shan, Liu Chun-Xiang, Wang Xian-Liang, Mao Jing-Yuan
Cardiovascular Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Evid Based Complement Alternat Med. 2019 Jul 22;2019:8512405. doi: 10.1155/2019/8512405. eCollection 2019.
At present, the prevention and treatment of cardiovascular disease in the world are facing severe challenges. Xinmailong injection, which is derived from the animal medicine , has certain advantages in the clinical treatment of cardiovascular disease. This study systematically evaluated the basic research reports of Xinmailong Injection on cardiovascular disease and made its pharmacological mechanisms more clear.
Basic research reports on the intervention mechanisms of Xinmailong Injection on cardiovascular disease in PubMed, EMBASE, Cochrane Library (No. 2, 2019), CNKI, Wan Fang, and VIP databases were searched. The search time limit was from the establishment of the database to February 2019. The literature was screened according to inclusion and exclusion criteria, and then the data were extracted and a descriptive analysis of the pharmacological mechanisms of Xinmailong Injection on cardiovascular disease was performed.
Finally, twenty-two basic research reports were included. The intervention mechanisms of Xinmailong Injection on cardiovascular disease mainly includes the following: inhibiting oxidative stress and inflammatory reaction; regulating autophagy; promoting Ca influx by activating excitability of excitation-contraction coupling (ECC); inhibiting overexpressions of transforming growth factor-1 (TGF-1) and connective tissue growth factor (CTGF) to regulate the dynamic balance of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs); inhibiting the phosphorylation of extracellular regulated protein kinases 1/2 (ERK1/2), protein kinase B (AKT), and glycogen synthase kinase 3 (GSK3) proteins and overexpression of the downstream transcription factor GATA4 in the nucleus; regulating vascular endothelial factors and so on.
Xinmailong Injection can protect cardiomyocytes and maintain the normal function of the heart in various ways, thus effectively preventing the development of cardiovascular disease. Therefore, Xinmailong Injection has great potential for clinical application, and more basic researches need to be carried out to explore the medicinal value of Xinmailong Injection.
目前,全球心血管疾病的防治面临严峻挑战。源于动物药的心脉隆注射液在心血管疾病临床治疗中具有一定优势。本研究系统评价了心脉隆注射液治疗心血管疾病的基础研究报道,使其药理机制更加明确。
检索PubMed、EMBASE、Cochrane Library(2019年第2期)、中国知网、万方和维普数据库中关于心脉隆注射液干预心血管疾病机制的基础研究报道。检索时限为各数据库建库至2019年2月。按照纳入与排除标准筛选文献,然后提取数据并对心脉隆注射液治疗心血管疾病的药理机制进行描述性分析。
最终纳入22篇基础研究报道。心脉隆注射液干预心血管疾病的机制主要包括:抑制氧化应激和炎症反应;调节自噬;通过激活兴奋-收缩偶联(ECC)兴奋性促进Ca内流;抑制转化生长因子-1(TGF-1)和结缔组织生长因子(CTGF)过表达以调节基质金属蛋白酶(MMPs)和基质金属蛋白酶组织抑制剂(TIMPs)的动态平衡;抑制细胞外调节蛋白激酶1/2(ERK1/2)、蛋白激酶B(AKT)和糖原合酶激酶3(GSK3)蛋白磷酸化以及下游转录因子GATA4在细胞核内的过表达;调节血管内皮因子等。
心脉隆注射液可通过多种方式保护心肌细胞,维持心脏正常功能,从而有效预防心血管疾病的发展。因此,心脉隆注射液具有很大的临床应用潜力,需要开展更多基础研究以探索心脉隆注射液的药用价值。